Investor Relations
Investor Relations
Corporate Profile
Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Feb 25
2021
2021
Allogene Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Learn More >
Feb 18
2021
2021
Allogene Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results on February 25, 2021
Learn More >
Feb 09
2021
2021
Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences
Learn More >
Jan 26
2021
2021
Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the 2021 Jeantet-Collen Prize for Translational Medicine
Learn More >
Jan 05
2021
2021
Allogene Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
Learn More >
Dec 23
2020
2020
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma
Learn More >
Dec 15
2020
2020
Allogene Therapeutics and Overland Pharmaceuticals Form Joint Venture in Greater China to Develop and Commercialize AlloCAR T™ Cell Therapies
Learn More >
Dec 07
2020
2020
Allogene Therapeutics Presents Preclinical Findings Supporting ALLO-605, the First Anti-BCMA TurboCAR™ T Cell Therapy, at the 62nd Meeting of the American Society of Hematology
Learn More >
Dec 06
2020
2020
Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology
Learn More >
Dec 05
2020
2020